Cognition Therapeutics Initiates Public Offering of Common Stock to Advance Neurodegenerative Disorder Treatments
PURCHASE, N.Y. – Cognition Therapeutics, a leading biopharmaceutical company focused on developing treatments for neurodegenerative disorders, has announced the launch of an underwritten public offering of its common stock. The company aims to raise funds to further advance its innovative therapies for conditions such as Alzheimer’s disease, dementia with Lewy bodies, and dry age-related macular degeneration.
In addition to the primary offering, Cognition Therapeutics will grant the underwriter a 30-day option to purchase additional shares, potentially increasing the total number of shares sold by up to 15%. The completion of the offering is subject to market conditions, and there is no guarantee of its successful closure or final terms.
Titan Partners Group, a division of American Capital Partners, has been appointed as the sole book-running manager for the offering. The sale will be conducted under a shelf registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (SEC) in late December and declared effective at the beginning of January.
Investors interested in participating in the offering can access the preliminary prospectus supplement and accompanying prospectus on the SEC’s website or by contacting Titan Partners Group for more information on the terms of the offering.
Cognition Therapeutics is currently focused on advancing its lead candidate, CT1812, through clinical trials for various neurodegenerative disorders. The company’s innovative portfolio of σ-2 receptor modulators shows promise in regulating pathways affected by these diseases, offering hope for patients and caregivers alike.
While the company’s forward-looking statements reflect its current expectations, there are inherent risks and uncertainties that may impact actual results. This press release serves as a notification of the offering and does not constitute a solicitation to buy or sell securities where prohibited by law.
For more information on Cognition Therapeutics and its groundbreaking research, interested parties can refer to the official press release from the company.
